RxDoctor Payments Data

Susan Lipsy

Adult Health · Syracuse, NYNPI 1265525778

Payments from drug & device makers

$3,852in general payments, 2019–2025

Across 145 payments — averaging $26.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$428
  • 180 Medical, Inc.$379
  • Coloplast$315
  • Urovant Sciences Inc$274
  • AbbVie$236
  • Merck$221
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,852 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$56,619
Medicare patients
403
Services billed
1,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron179$132,264
GemtesaVibegron56$43,035
Mirabegron ErMirabegron27$24,794
Methenamine Hippurate189$10,700
Tamsulosin Hcl596$7,366
VesicareSolifenacin Succinate13$4,928
Solifenacin Succinate109$4,150
Alfuzosin Hcl ErAlfuzosin Hcl173$4,092
Oxybutynin Chloride ErOxybutynin Chloride139$3,551
Trospium Chloride ErTrospium Chloride20$2,341
Fesoterodine Fumarate ErFesoterodine Fumarate11$2,074
Silodosin23$1,745
Testosterone21$1,673
Finasteride144$1,515
Trospium Chloride24$1,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Vesicare$428$137,192192 claims
Sumitomo Pharma America, Inc.Gemtesa$88$43,03556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.

Other adult health in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →